|Videos|January 27, 2022
MRD Results and Guiding Treatment Decisions
Kashyap Patel, MD, and Jason Starr, DO, explain the various potential uses for MRD results and how they guide treatment decisions.
Advertisement
Episodes in this series
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
Keynote Address Tackles AI’s Role in Health Care, Eye Care
3
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
4
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
5